Connor, Clark & Lunn Investment Management (CC&L)’s Cogent Biosciences COGT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-136,450	Closed	-$5.25M	–	1656
2026 Q1	$5.25M	Sell	136,450 -39,439	-22%	-$1.46M	0.01%	673
2025 Q4	$6.25M	Buy	+175,889	New	+$4.94M	0.02%	586
2024 Q1	–	Sell	-83,600	Closed	-$492K	–	1552
2023 Q4	$492K	Sell	83,600 -142,288	-63%	-$1.09M	﹤0.01%	1050
2023 Q3	$2.2M	Sell	225,888 -50,194	-18%	-$595K	0.01%	593
2023 Q2	$3.27M	Buy	276,082 +1,167	+0.4%	+$13.4K	0.02%	480
2023 Q1	$2.97M	Buy	274,915 +1,931	+0.7%	+$24.7K	0.02%	471
2022 Q4	$3.16M	Buy	272,984 +12,689	+5%	+$157K	0.02%	447
2022 Q3	$3.88M	Buy	260,295 +86,087	+49%	+$1.18M	0.03%	370
2022 Q2	$1.57M	Buy	+174,208	New	+$1.19M	0.01%	519

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s COGT Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 136,450 shares — an estimated $5.25M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in COGT in Q2 2022 and held it in 9 quarters. The position peaked at $6.25M in Q4 2025. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 136,450 Cogent Biosciences shares in Q2 2026, an estimated $5.25M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Cogent Biosciences in Q2 2022 and held it in 9 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Cogent Biosciences position peaked at $6.25M in Q4 2025.
322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.